Michigan is currently home to 2224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Safety and Effectiveness of Primary Hybrid Construct of Mobi-C and ACDF in the Treatment of Two-level Symptomatic Degenerative Disc Disease in the Cervical Spine.
NCT06485206
Recruiting
The study is a prospective, multi-center cohort study of patients with two-level DDD implanted with CDA adjacent to ACDF (hybrid construct). The overall success of the hybrid procedure will be compared to 2-level ACDF historical controls from the Mobi-C IDE trial. 97 patients will receive the hybrid surgery and will be followed for a minimum of 2 years.
Gender:
ALL
Ages:
Between 22 years and 69 years
Trial Updated:
01/23/2025
Locations: Michigan Orthopaedic Surgeons, Southfield, Michigan
Conditions: Degenerative Disc Disease
Register for Updates
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT04986423
Recruiting
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) dise... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Role of Home-Based Transcutaneous Electrical Acustimulation for Treatment of Pain in Subjects With Chronic Pancreatitis
NCT06721572
Recruiting
Transcutaneous Electrical Acustimulation (TEA) is a noninvasive acupuncture method that can be self-administered at home without needles. TEA transmits a weak electrical current using electrodes placed at acupoints and has shown to safely reduce pain in other gastrointestinal conditions. This study will help elucidate if TEA is effective in treating abdominal pain in patients with painful chronic pancreatitis (CP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Chronic Pancreatitis, Pancreatitis
Register for Updates
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
NCT06524635
Recruiting
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS and AD. This study will consist of 2 sub-studies: Sub-Study 1 moderate to severe hidradeni... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/22/2025
Locations: University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor, Michigan
Conditions: Hidradenitis Suppurativa, Atopic Dermatitis
Register for Updates
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
NCT06109181
Recruiting
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/22/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Register for Updates
A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD
NCT05643638
Recruiting
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Graft Versus Host Disease, Acute
Register for Updates
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
NCT04748601
Recruiting
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
01/22/2025
Locations: Upsher-Smith Clinical Trial Site #2, Ann Arbor, Michigan
Conditions: Migraine Disorders
Register for Updates
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
NCT04077762
Recruiting
This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization. Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. Randomization will be performed in blocks of 50 per site. Similarly, a second sub-randomization will be performed in the femoral access group int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Patient Satisfaction, Vascular Access Complication
Register for Updates
Exparel Injection for Postoperative Orbital Pain
NCT02381353
Recruiting
After surgery to remove the eye, either by enucleation or evisceration, patients have variable levels of pain for several postoperative days. Some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale. The current operative standard is to infiltrate the eye socket with 0.5% bupivacaine during surgery leading to several hours of postoperative analgesia. In 2011, Pacira Pharmaceuticals released a bu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Michigan Kellogg Eye Institute, Ann Arbor, Michigan
Conditions: Pain, Postoperative
Register for Updates
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
NCT06568367
Recruiting
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Lathrup Village, Michigan
Conditions: Excessive Sleepiness, Shift-work Disorder
Register for Updates
The Breakfast Study
NCT05986097
Recruiting
The investigators will conduct an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, very low-carbohydrate breakfast-focused program in 120 adults with type 2 diabetes. The investigators will measure acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/21/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes
Register for Updates
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066
Recruiting
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
01/21/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Register for Updates